#modernarisesover12%
modernarisesover12%
Hot
Latest
#modernarisesover12% 🚀 $MRNAon
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
AngelOfCrypto_-:
👍👍👍
#ModernaRisesOver12% #ModernaRisesOver12%
Moderna shares surged more than 12%, making it one of the best-performing stocks in the S&P 500, after the company unveiled promising new pipeline developments during its Science Day investor event.
Key points:
Investors reacted positively to Moderna's first in vivo CAR-T program targeting autoimmune diseases, including systemic lupus erythematosus.
The company highlighted progress across its cancer, autoimmune, and next-generation mRNA programs, reinforcing confidence that it is expanding beyond COVID-19 vaccines.
Analysts also pointed to upcoming catalysts, including an FDA decision on Moderna's seasonal flu vaccine later this year, as additional drivers for investor optimism.
Moderna shares surged more than 12%, making it one of the best-performing stocks in the S&P 500, after the company unveiled promising new pipeline developments during its Science Day investor event.
Key points:
Investors reacted positively to Moderna's first in vivo CAR-T program targeting autoimmune diseases, including systemic lupus erythematosus.
The company highlighted progress across its cancer, autoimmune, and next-generation mRNA programs, reinforcing confidence that it is expanding beyond COVID-19 vaccines.
Analysts also pointed to upcoming catalysts, including an FDA decision on Moderna's seasonal flu vaccine later this year, as additional drivers for investor optimism.
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
A 12%+ jump isn't something the market ignores. $MRNA.US has grabbed investors' attention with fresh bullish momentum, supported by encouraging vaccine developments and renewed market confidence.
📈 Strong moves can be exciting—but smart investors know that patience often beats FOMO.
The trend looks positive, yet every rally deserves careful analysis before making a decision. Risk management always comes first.
💬 Do you think $MRNA.US can break even higher, or is a healthy pullback coming first?
#ModernaRisesOver12% #Velvet #Stocks #Biotech #Investing #MarketNews $VELVET $MRNA.US
📈 Strong moves can be exciting—but smart investors know that patience often beats FOMO.
The trend looks positive, yet every rally deserves careful analysis before making a decision. Risk management always comes first.
💬 Do you think $MRNA.US can break even higher, or is a healthy pullback coming first?
#ModernaRisesOver12% #Velvet #Stocks #Biotech #Investing #MarketNews $VELVET $MRNA.US
#ModernaRisesOver12% #Velvet
In a remarkable turn of events, $MRNA has achieved an impressive milestone by hitting a 52-week high, signaling a significant resurgence in its market performance. 📈 Specifically, shares of Moderna soared by more than 12%, reaching an encouraging price of $67.78, a movement largely fueled by the robust momentum currently being experienced within the biotechnology sector. This upward trajectory has been bolstered further by the recent decision from an FDA panel, which has officially endorsed Moderna’s innovative mRNA flu vaccine, lending credibility and support to the company’s cutting-edge portfolio. In addition to this positive news, analysts have responded favorably, raising their price target for the stock to an optimistic $77, reflecting increased confidence in the company’s growth potential. Moreover, the firm continues to demonstrate strong advancements within its pipeline and capitalizes on the rising global demand for its pioneering medical solutions. As the market continues to show bullish tendencies, it seems that buyers are eagerly stepping in, driving the stock price ever higher and solidifying belief in Moderna's promising future.
$VELVET
In a remarkable turn of events, $MRNA has achieved an impressive milestone by hitting a 52-week high, signaling a significant resurgence in its market performance. 📈 Specifically, shares of Moderna soared by more than 12%, reaching an encouraging price of $67.78, a movement largely fueled by the robust momentum currently being experienced within the biotechnology sector. This upward trajectory has been bolstered further by the recent decision from an FDA panel, which has officially endorsed Moderna’s innovative mRNA flu vaccine, lending credibility and support to the company’s cutting-edge portfolio. In addition to this positive news, analysts have responded favorably, raising their price target for the stock to an optimistic $77, reflecting increased confidence in the company’s growth potential. Moreover, the firm continues to demonstrate strong advancements within its pipeline and capitalizes on the rising global demand for its pioneering medical solutions. As the market continues to show bullish tendencies, it seems that buyers are eagerly stepping in, driving the stock price ever higher and solidifying belief in Moderna's promising future.
$VELVET
#ModernaRisesOver12%
🟢 MODERNA +12% — mRNA Giant Making a Comeback?
#ModernaRisesOver12% | #MRNA | #Biotech | #mRNA
Moderna stock ripped 12%+ on June 26, climbing from ~$46 at the start of the month to nearly $69 intraday. That's a 48% move in under four weeks. Here's what's driving it.
The FDA Vote Was the Main Catalyst
An FDA advisory committee voted 9-0 in favor of Moderna's mRNA flu vaccine (mFLUSIVA) for adults 50 and older. In biotech, a unanimous panel result is as close to a guaranteed approval as it gets. The official FDA decision date is August 5, 2026 — now the most important date on every MRNA trader's calendar. If approved, Moderna finally has a recurring seasonal revenue stream beyond COVID boosters.
Everything Else Stacked On Top
On June 25, Moderna held a Science Day showcasing its full pipeline — oncology, rare diseases, autoimmune conditions, and an AI-driven R&D engine. Management also restructured the company around three commercial franchises with multiple product launches planned for 2027-2028. That alone pushed the stock 6%+. Then came news of German manufacturing expansion, including interest in BioNTech facilities set to close — sending shares up another 8-12% across sessions. Analyst upgrades from Piper Sandler, Goldman Sachs, and Evercore ISI added fuel.
The Reality Check
Moderna is still losing money. Q1 2026 revenue was just $389M with a net loss of ~$1.34B. Jefferies kept a Hold rating and $45 target, noting flu revenues likely don't ramp until 2027. The stock is trading on narrative and probability — not profits. Yet.
That tension between strong science and lagging earnings is exactly what makes MRNA a trader's stock right now.
August 5 is the next big date. Are you watching it? 👇
#Moderna #MRNA #FDAApproval #BiotechStocks #BinanceSquare
🟢 MODERNA +12% — mRNA Giant Making a Comeback?
#ModernaRisesOver12% | #MRNA | #Biotech | #mRNA
Moderna stock ripped 12%+ on June 26, climbing from ~$46 at the start of the month to nearly $69 intraday. That's a 48% move in under four weeks. Here's what's driving it.
The FDA Vote Was the Main Catalyst
An FDA advisory committee voted 9-0 in favor of Moderna's mRNA flu vaccine (mFLUSIVA) for adults 50 and older. In biotech, a unanimous panel result is as close to a guaranteed approval as it gets. The official FDA decision date is August 5, 2026 — now the most important date on every MRNA trader's calendar. If approved, Moderna finally has a recurring seasonal revenue stream beyond COVID boosters.
Everything Else Stacked On Top
On June 25, Moderna held a Science Day showcasing its full pipeline — oncology, rare diseases, autoimmune conditions, and an AI-driven R&D engine. Management also restructured the company around three commercial franchises with multiple product launches planned for 2027-2028. That alone pushed the stock 6%+. Then came news of German manufacturing expansion, including interest in BioNTech facilities set to close — sending shares up another 8-12% across sessions. Analyst upgrades from Piper Sandler, Goldman Sachs, and Evercore ISI added fuel.
The Reality Check
Moderna is still losing money. Q1 2026 revenue was just $389M with a net loss of ~$1.34B. Jefferies kept a Hold rating and $45 target, noting flu revenues likely don't ramp until 2027. The stock is trading on narrative and probability — not profits. Yet.
That tension between strong science and lagging earnings is exactly what makes MRNA a trader's stock right now.
August 5 is the next big date. Are you watching it? 👇
#Moderna #MRNA #FDAApproval #BiotechStocks #BinanceSquare
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12% #ModernaRisesOver12%
Shares of Moderna rose more than 12%, indicating strong investor optimism.
Potential drivers include:
Positive clinical trial or vaccine development updates.
Favorable regulatory news or approvals.
Better-than-expected earnings or improved revenue guidance.
Increased investor interest in biotech stocks or renewed demand for mRNA-based therapies.
A double-digit gain in a single session typically reflects a meaningful catalyst or a sharp shift in market sentiment, prompting investors to reassess the company's growth prospects.
Shares of Moderna rose more than 12%, indicating strong investor optimism.
Potential drivers include:
Positive clinical trial or vaccine development updates.
Favorable regulatory news or approvals.
Better-than-expected earnings or improved revenue guidance.
Increased investor interest in biotech stocks or renewed demand for mRNA-based therapies.
A double-digit gain in a single session typically reflects a meaningful catalyst or a sharp shift in market sentiment, prompting investors to reassess the company's growth prospects.
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12%
Moderna Inc. $MRNAon ignited the stock market with a massive rally, surging over 12% to hit a brand new 52-week high near $67.80. This powerful momentum comes as a relief to investors, marking a stellar year-to-date gain of over 100% from its deep lows.
The primary catalyst? Wall Street is officially cheering Moderna’s deep clinical pipeline that goes far beyond COVID-19. Investors reacted heavily to the company’s recent "Science Day" presentation, which showcased groundbreaking advancements in mRNA-based cancer antigen therapies and autoimmune treatments. Furthermore, an FDA advisory panel recently voted a unanimous 9-0 in favor of Moderna’s new seasonal flu vaccine (mRNA-1010), setting up a massive catalyst for official approval this August.
As capital rotates from volatile tech and chip stocks into high-potential healthcare names, top institutional firms like Piper Sandler have promptly raised their price targets to $77. Tech indicators show strong bullish momentum, proving that Moderna’s transformation into a diversified biotech giant is fully underway.
#ModernaRisesOver12% #StockMarketNews #Biotech #Investing #MRNA #mRNA #FinanceUpdate #WallStreet
Moderna Inc. $MRNAon ignited the stock market with a massive rally, surging over 12% to hit a brand new 52-week high near $67.80. This powerful momentum comes as a relief to investors, marking a stellar year-to-date gain of over 100% from its deep lows.
The primary catalyst? Wall Street is officially cheering Moderna’s deep clinical pipeline that goes far beyond COVID-19. Investors reacted heavily to the company’s recent "Science Day" presentation, which showcased groundbreaking advancements in mRNA-based cancer antigen therapies and autoimmune treatments. Furthermore, an FDA advisory panel recently voted a unanimous 9-0 in favor of Moderna’s new seasonal flu vaccine (mRNA-1010), setting up a massive catalyst for official approval this August.
As capital rotates from volatile tech and chip stocks into high-potential healthcare names, top institutional firms like Piper Sandler have promptly raised their price targets to $77. Tech indicators show strong bullish momentum, proving that Moderna’s transformation into a diversified biotech giant is fully underway.
#ModernaRisesOver12% #StockMarketNews #Biotech #Investing #MRNA #mRNA #FinanceUpdate #WallStreet
#ModernaRisesOver12% $BTC
🚀 BINANCE SQUARE READY POST 🚀
🧬 #ModernaRisesOver12% — Smart Money Rotating In? 📈
Big moves are getting attention across the market as Moderna surged over 12%, putting biotech back on traders’ watchlists. 👀🔥
Momentum like this often sparks discussions around:
✅ Institutional interest
✅ Market sentiment shifts
✅ Short-term volatility opportunities
✅ Sector rotation narratives
But remember — one green candle doesn’t automatically mean a long-term trend. Stay disciplined, manage risk, and watch volume + follow-through before making decisions. 📊
💬 Question for the community:
Is this the start of a bigger biotech comeback… or just a short-term hype move?
Drop your thoughts below ⬇️
🔥 Follow JALILORD9 for more market updates, crypto trends & opportunity alerts.
#BinanceSquare #Stocks #Moderna #Trading #Crypto #Investing #MarketNews #Bullish #JALILORD9
🚀 BINANCE SQUARE READY POST 🚀
🧬 #ModernaRisesOver12% — Smart Money Rotating In? 📈
Big moves are getting attention across the market as Moderna surged over 12%, putting biotech back on traders’ watchlists. 👀🔥
Momentum like this often sparks discussions around:
✅ Institutional interest
✅ Market sentiment shifts
✅ Short-term volatility opportunities
✅ Sector rotation narratives
But remember — one green candle doesn’t automatically mean a long-term trend. Stay disciplined, manage risk, and watch volume + follow-through before making decisions. 📊
💬 Question for the community:
Is this the start of a bigger biotech comeback… or just a short-term hype move?
Drop your thoughts below ⬇️
🔥 Follow JALILORD9 for more market updates, crypto trends & opportunity alerts.
#BinanceSquare #Stocks #Moderna #Trading #Crypto #Investing #MarketNews #Bullish #JALILORD9
#ModernaRisesOver12%
🚀 #ModernaRisesOver12%
📈 Moderna shares surged **more than 12%**, marking one of the strongest moves in the healthcare sector. The rally has drawn attention from investors as the biotechnology company experienced a sharp increase in buying activity.
🧬 Biotech stocks can move significantly based on clinical trial results, regulatory updates, product developments, earnings reports, or changes in investor sentiment.
🔍 Why this matters:
• Strong gains can boost confidence in the biotech sector.
• Increased trading volume often reflects heightened investor interest.
• Healthcare stocks can influence broader market performance.
• Positive momentum may attract both institutional and retail investors.
⚠️ While a double-digit gain is impressive, biotech stocks are known for their volatility. Future price movements will depend on company fundamentals, financial performance, and upcoming developments.
📊 Investors should focus on long-term fundamentals, diversify their portfolios, and avoid making decisions based solely on short-term price swings.
#Moderna #Biotech #Healthcare #StockMarket #Investing #Trading #Finance #Stocks #MarketUpdate #Innovation
$BTC
🚀 #ModernaRisesOver12%
📈 Moderna shares surged **more than 12%**, marking one of the strongest moves in the healthcare sector. The rally has drawn attention from investors as the biotechnology company experienced a sharp increase in buying activity.
🧬 Biotech stocks can move significantly based on clinical trial results, regulatory updates, product developments, earnings reports, or changes in investor sentiment.
🔍 Why this matters:
• Strong gains can boost confidence in the biotech sector.
• Increased trading volume often reflects heightened investor interest.
• Healthcare stocks can influence broader market performance.
• Positive momentum may attract both institutional and retail investors.
⚠️ While a double-digit gain is impressive, biotech stocks are known for their volatility. Future price movements will depend on company fundamentals, financial performance, and upcoming developments.
📊 Investors should focus on long-term fundamentals, diversify their portfolios, and avoid making decisions based solely on short-term price swings.
#Moderna #Biotech #Healthcare #StockMarket #Investing #Trading #Finance #Stocks #MarketUpdate #Innovation
$BTC
Moderna ($MRNAon ) Skyrockets Over 12%! Biotech Rally Sparks Market Interest
The traditional stock market is witnessing massive movements as Moderna ($MRNAon ) surges nearly 13%, hitting a fresh 52-week high of $67.78!
The explosive rally comes right after Moderna hosted its highly anticipated Science Day event, where it showcased a powerful pipeline of upcoming mRNA advancements—including oncology (cancer therapies) and a unanimous FDA advisory committee nod for its seasonal flu vaccine ($mRNA-1010).
While tech and AI chip stocks faced heavy volatility and pulled back, capital rotated aggressively into the healthcare and biotech sectors.
💡 Key Takeaways for Crypto & Macro Traders:
× The Biotech Pivot: Major institutional interest is returning to biotech and mRNA technology breakthroughs.
× Liquidity Rotation: When tech giants take a breather, macro liquidity frequently shifts to defensive and innovation-heavy sectors like healthcare.
× Crypto Correlation: Sharp stock market movements often influence overall high-risk asset sentiment, keeping crypto traders on alert for macro volatility.
Are you watching traditional equity markets for clues on the next big crypto move, or focusing purely on $BTC and $ETH ? Let's discuss in the comments! 👇
#writetoearn #ModernaRisesOver12% #Write2Earn #Biotech #MacroNews
The traditional stock market is witnessing massive movements as Moderna ($MRNAon ) surges nearly 13%, hitting a fresh 52-week high of $67.78!
The explosive rally comes right after Moderna hosted its highly anticipated Science Day event, where it showcased a powerful pipeline of upcoming mRNA advancements—including oncology (cancer therapies) and a unanimous FDA advisory committee nod for its seasonal flu vaccine ($mRNA-1010).
While tech and AI chip stocks faced heavy volatility and pulled back, capital rotated aggressively into the healthcare and biotech sectors.
💡 Key Takeaways for Crypto & Macro Traders:
× The Biotech Pivot: Major institutional interest is returning to biotech and mRNA technology breakthroughs.
× Liquidity Rotation: When tech giants take a breather, macro liquidity frequently shifts to defensive and innovation-heavy sectors like healthcare.
× Crypto Correlation: Sharp stock market movements often influence overall high-risk asset sentiment, keeping crypto traders on alert for macro volatility.
Are you watching traditional equity markets for clues on the next big crypto move, or focusing purely on $BTC and $ETH ? Let's discuss in the comments! 👇
#writetoearn #ModernaRisesOver12% #Write2Earn #Biotech #MacroNews
Verified
#modernarisesover12% #Velvet
🚀 $MRNAon hits 52-week high at $67.78, +12%+
Drivers:
✅ FDA panel backs mRNA flu vaccine
✅ Analyst PT raised to $77
✅ Pipeline progress + global demand up
Momentum stays bullish as buyers hold control.
📊 Trading view: BUY on pullback only.
Avoid chasing after +12% day. Wait for support retest for better entry.
$MRNA.US $VELVET
News GURUU
🚀 $MRNAon hits 52-week high at $67.78, +12%+
Drivers:
✅ FDA panel backs mRNA flu vaccine
✅ Analyst PT raised to $77
✅ Pipeline progress + global demand up
Momentum stays bullish as buyers hold control.
📊 Trading view: BUY on pullback only.
Avoid chasing after +12% day. Wait for support retest for better entry.
$MRNA.US $VELVET
News GURUU
AngelOfCrypto_-:
👍
#ModernaRisesOver12% #ModernaRisesOver12%
A 12% rally is exciting, but one strong day doesn't define a long-term investment.
Sharp gains often follow positive news, strong earnings, or improving market sentiment.
Rather than chasing momentum, I prefer to ask:
"Is this move backed by stronger fundamentals, or is it just short-term excitement?"
The best investors stay patient, do their research, and let the data—not emotions—guide their decisions.
#Moderna #Stocks #Investing #MarketNews
A 12% rally is exciting, but one strong day doesn't define a long-term investment.
Sharp gains often follow positive news, strong earnings, or improving market sentiment.
Rather than chasing momentum, I prefer to ask:
"Is this move backed by stronger fundamentals, or is it just short-term excitement?"
The best investors stay patient, do their research, and let the data—not emotions—guide their decisions.
#Moderna #Stocks #Investing #MarketNews
MRNAonAlpha
MRNAUS+12.64%
Moderna jumped more than 12% after sharing encouraging updates on its pipeline, including new cancer and autoimmune treatments. Investors are looking beyond COVID vaccines and focusing on the company's long-term growth potential. Now the focus shifts to upcoming clinical results and regulatory decisions.
#ModernaRisesOver12%
#ModernaRisesOver12%
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12% Moderna ($MRNA) Surges Over 12%, Hitting 52-Week Highs on Pipeline Breakthroughs 🚀
Moderna is proving there is life—and massive growth—well beyond COVID-19 vaccines. The stock surged over 12% on Friday, hitting a 52-week high of $67.78, fueled by a highly successful "Science Day" investor presentation.
Investors are rallying behind strong diversification milestones, including:
Unanimous FDA Advisory Support: A clean 9-0 vote favoring their investigational seasonal flu vaccine (mRNA-1010) ahead of its August PDUFA date.
Oncology Breakthroughs: Exciting pipeline updates regarding cancer antigen therapies (like mRNA-4194 for Lynch Syndrome).
Autoimmune Progress: Advancing the mRNA-6007 CAR-T program into early development for Lupus.
With Wall Street targets shifting upwards (Piper Sandler raised its target to $77), Moderna is successfully reshaping its narrative into a diversified mRNA powerhouse.
#Biotech #StockMarket #MrNaveed #Investing
Moderna is proving there is life—and massive growth—well beyond COVID-19 vaccines. The stock surged over 12% on Friday, hitting a 52-week high of $67.78, fueled by a highly successful "Science Day" investor presentation.
Investors are rallying behind strong diversification milestones, including:
Unanimous FDA Advisory Support: A clean 9-0 vote favoring their investigational seasonal flu vaccine (mRNA-1010) ahead of its August PDUFA date.
Oncology Breakthroughs: Exciting pipeline updates regarding cancer antigen therapies (like mRNA-4194 for Lynch Syndrome).
Autoimmune Progress: Advancing the mRNA-6007 CAR-T program into early development for Lupus.
With Wall Street targets shifting upwards (Piper Sandler raised its target to $77), Moderna is successfully reshaping its narrative into a diversified mRNA powerhouse.
#Biotech #StockMarket #MrNaveed #Investing
MRNAonAlpha
MRNAUS+12.64%
🚀 MRNA Explodes 12.59%! Is Biotech Back? 📈
Moderna ($MRNA) skyrocketed yesterday, closing at $67.27 (hitting a high of $69.28)!
What happened?
FDA Win: Advisory committee voted 100% YES on Moderna's new flu vaccine (mRNA-1010).
Next-Gen Tech: Advanced a major new therapy (mRNA-6007) for autoimmune diseases like Lupus.
Roadmap: CEO confirmed the company will hit cash breakeven by 2028.Price Targets: Wall Street analysts instantly upgraded targets up to $77.
Next Big Date: 🎯 August 5, 2026 (Official FDA approval decision).
Are you buying this breakout or waiting for a pullback? 👇
#modernarisesover12%
Moderna ($MRNA) skyrocketed yesterday, closing at $67.27 (hitting a high of $69.28)!
What happened?
FDA Win: Advisory committee voted 100% YES on Moderna's new flu vaccine (mRNA-1010).
Next-Gen Tech: Advanced a major new therapy (mRNA-6007) for autoimmune diseases like Lupus.
Roadmap: CEO confirmed the company will hit cash breakeven by 2028.Price Targets: Wall Street analysts instantly upgraded targets up to $77.
Next Big Date: 🎯 August 5, 2026 (Official FDA approval decision).
Are you buying this breakout or waiting for a pullback? 👇
#modernarisesover12%
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS+12.64%
#ModernaRisesOver12% Moderna shares rose around 12–13% after an investor event highlighted new work in autoimmune treatments using its mRNA platform and CAR-T approaches. Investors seem to be viewing this as evidence that Moderna is broadening beyond COVID products. �
The Wall Street Journal +1
• There is also optimism around its cancer pipeline, including melanoma-vaccine programs and other oncology projects that analysts have been watching closely. �
biopharmadive.com +1
• Earlier concerns around patent litigation have eased somewhat after a settlement removed part of the uncertainty hanging over the company, even though costs remain significant. �
Stocktwits
• Moderna has continued projecting a return to growth with additional vaccine approvals and international partnerships supporting revenue. �
SEC +1
The interesting contrast today is that while AI chip names such as Kioxia were falling sharply, healthcare stocks — especially Moderna — moved in the opposite direction. �#ModernaRisesOver12% #KioxiaADRFallsOver14% BitcoinTests$58000#AAVERises8.9%
The Wall Street Journal +1
• There is also optimism around its cancer pipeline, including melanoma-vaccine programs and other oncology projects that analysts have been watching closely. �
biopharmadive.com +1
• Earlier concerns around patent litigation have eased somewhat after a settlement removed part of the uncertainty hanging over the company, even though costs remain significant. �
Stocktwits
• Moderna has continued projecting a return to growth with additional vaccine approvals and international partnerships supporting revenue. �
SEC +1
The interesting contrast today is that while AI chip names such as Kioxia were falling sharply, healthcare stocks — especially Moderna — moved in the opposite direction. �#ModernaRisesOver12% #KioxiaADRFallsOver14% BitcoinTests$58000#AAVERises8.9%
#ModernaRisesOver12%
$MRNAon Hits A52_week High
Modern surged over 12 %to $67.78 driven by strong biotech momentum
FDA panel backs it's mRNA fou vaccine
#midern
$MRNAon Hits A52_week High
Modern surged over 12 %to $67.78 driven by strong biotech momentum
FDA panel backs it's mRNA fou vaccine
#midern
Log in to explore more content